The short version of GLP-1 receptor fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
=== Specialized to men === Since HSDD in men is not acknowledged and was categorized to be a distinct sexual dysfunction, there are currently no drugs specialized for men in similar conditions as stated above.
Roberts (2001) presented a spectrum of responses to be expected under a variety of flux rate conditions varying from very slow seepage to rapid venting. Very-slow-seepage sites do not support complex chemosynthetic communities; rather, they usually only support simple microbial mats (Beggiatoa sp.). In the upper slope environment, the hard substrates resulting from carbonate precipitation can have associated communities of non-chemosynthetic animals, including a variety of sessile cnidarians such as corals and sea anemones. At the rapid flux end of the spectrum, fluidized sediment generally accompanies hydrocarbons and formation fluids arriving at the seafloor. Mud volcanoes and mud flows result. Somewhere between these two end members exists the conditions that support densely populated and diverse communities of chemosynthetic organisms (microbial mats, siboglinid tube worms, bathymodioline mussels, lucinid and vesicomyid clams, and associated organisms). These areas are frequently associated with surface or near-surface gas hydrate deposits. They also have localized areas of lithified seafloor, generally authigenic carbonates but sometimes more exotic minerals such as barite are present.
== Types == Dosage forms vary depending on the method/route of administration, which can include many types of liquid, solid, and semisolid forms. Common dosage forms include tablets, capsules, drinks, solutions, suspensions, and syrups, among others. A combination drug (or fixed-dose combination; FDC) is a product that contains more than one active ingredient (e.g., one tablet, one capsule, or one syrup with multiple drugs). In naturopathy, dosages can take the form of decoctions and herbal teas, in addition to the more conventional methods mentioned above.
== Culture == Birches have spiritual importance in several religions, both modern and historical. In Celtic cultures, the birch symbolises growth, renewal, stability, initiation, and adaptability because it is highly adaptive and able to sustain harsh conditions with casual indifference. Proof of this adaptability is seen in its easy and eager ability to repopulate areas damaged by forest fires or clearings. Birches are also associated with Tír na nÓg, the land of the dead and the Sidhe, in Gaelic folklore, and as such frequently appear in Scottish, Irish, and English folksongs and ballads in association with death, or fairies, or returning from the grave. The leaves of the silver birch tree are used in the festival of St George, held in Novosej and other villages in Albania.
Sources: en.wikipedia.org
The Macrobian ruler, who was elected based on his stature and beauty, replied instead with a challenge for his Persian counterpart in the form of an unstrung bow: if the Persians could manage to draw it, they would have the right to invade his country; but until then, they should thank the gods that the Macrobians never decided to invade their empire. The Macrobians were a regional power reputed for their advanced architecture and gold wealth, which was so plentiful that they shackled their prisoners in golden chains. During the classical period, the Barbara city-states of Mosylon, Opone, Mundus, Isis, Malao, Avalites, Essina, Nikon and Sarapion developed a lucrative trade network, connecting with merchants from Ptolemaic Egypt, Ancient Greece, Phoenicia, Parthian Persia, Saba, the Nabataean Kingdom, and the Roman Empire. They used the ancient Somali maritime vessel known as the beden to transport their cargo.
Due to their effects and symptoms, Datura species have occasionally been used not only as poisons, but also as hallucinogens by various groups throughout history. Traditionally, their psychoactive administration has often been associated with witchcraft and sorcery or similar practices in many cultures, including the Western world. Certain common Datura species have also been used ritualistically as entheogens by some Native American groups. Non-psychoactive use of plants in the genus is usually done for medicinal purposes, and the alkaloids present in some species have long been considered traditional medicines in both the New and Old Worlds due to the presence of the alkaloids scopolamine and atropine, which are also produced by plants associated with Old World medicine such as Hyoscyamus niger, Atropa belladonna and Mandragora officinarum.
=== Social views === The use of modafinil as a supposed cognitive enhancer may be considered as cheating, unnatural, or risky. The University of Sussex explained that it is a prescription drug and the decision should be made by the doctor on whether to prescribe modafinil to a student. As a matter of bioethics, the US President's Council on Bioethics argued that excellence achieved through the use of drugs like modafinil is "cheap" as it obviates the need for hard work and study, and is not fully authentic because the excellence is partly attributable to the drug, not the individual. Alternately, people in Wall Street trading may consider it a tool for a competitive edge in a high-intensity environment. Due to such varying views, modafinil users for narcolepsy may cope with stigma by hiding, denying, or justifying their use, or by seeking support from others who share their views or experiences.
=== PDCAAS === The earlier "modern" measurement is the PDCAAS of 1989. For protein digestibility it compares the amount of protein-nitrogen that goes into a rat and out of the rat through feces, with a correction for "metabolic fecal protein": the amount of protein that occurs in feces when the rat is on a protein-free diet. For the amino acid score, it considers the quantity of each essential amino acid in the food as a proportion of the food's protein content and compares this to nutritional recommendations for preschool-age kids. The amino acid score used is that of the lowest, or 'limiting', amino acid. The amino acid score is then multiplied with the fecal digestibility score to get an overall score between zero and one. The PDCAAS has a tendency to over-estimate digestibility, because it measures feces instead of what remains at the end of the small intestine, where most protein absorption is believed to occur. Antinutrient factors like phytic acid and trypsin inhibitors may decrease absorption of protein, as does the absorption of protein by gut bacteria in the test subject's large intestine. In addition, older rats show lower PDCAAS-estimated fecal digestibility compared to young rats when the protein source contains anti-nutritional factors.
Overall the primary tank of the Iraqi forces was the T-55 tank. The Iraqis fielded them in great numbers. The Iraqis also had elements of two other independent armored brigades in theatre, those being the 50th and 29th Armored Brigades. Iraq would also field multiple Infantry Divisions. The Iraqis suffered the loss of over 3,000 tanks and over 2,000 other combat vehicles during these battles against the American-led coalition. It is estimated that Iraqi forces suffered 20,000–50,000 troops killed during combat operations. It is also estimated that over 75,000 Iraqi soldiers were wounded. Between 80,000 and 175,000 Iraqi troops were taken prisoner. Iraqi forces inflicted very minimal damage on Coalition forces.
Sources: en.wikipedia.org
Big dynorphin is an endogenous opioid peptide of the dynorphin family. It forms when a precursor protein prodynorphin is not fully processed, resulting in a 32-amino acid molecule containing both dynorphin A and dynorphin B sequences. It has the amino acid sequence: Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn-Gln-Lys-Arg-Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr. Big dynorphin is a highly efficiacious principal endogenous agonist at the human κ-opioid receptor (KOR). It produces one of the strongest responses at GPR139 receptor among dynorphins. Additionally, it uniquely modulates NMDA receptor and potentiates acid-sensing ion channel 1a (ASIC1a). It plays a role in pain and stress responses. It exhibits both analgesic and pro-nociceptive properties. In mice it modulates memory and learning, and has anxiolytic properties, contributing to homeostatic regulation of opioid signaling in the central nervous system.
== Reform and replacement == The Local Transport Act 2008 reconstituted it as the Greater Manchester Integrated Transport Authority. The integrated transport authority was replaced by Transport for Greater Manchester in 2011, which is accountable to the Greater Manchester Combined Authority.
Florey became the President of the Royal Society on 30 November 1960. Since 1873, the Royal Society had occupied Burlington House. While it had a sumptuous Meeting Room and Council Room, the administrative staff, who numbered about seventy in 1960, worked in cramped conditions in the awkward-to-access offices in the attic and basement. Florey decided to seek better accommodation. In December 1960, Florey was informed that plans to build new accommodation for the Foreign Office at Carlton House Terrace had fallen though and that the Crown Estate Commissioners had suggested that the premises might be suitable for the headquarters of cultural bodies. Florey inspected the property and lodged a formal application to occupy four houses on the site, numbers 6 to 9. Florey raised the money required to realise the architect Sir William Holford's vision for the interiors. While the government paid the rent and upkeep on the Royal Society's accommodation, about £45,000 in 1963 (equivalent to £822,000 in 2025), repairs and alterations were at the Royal Society's expense and ultimately came to around £850,000 (equivalent to £15,525,000 in 2025). The move was not completed during Florey's term of office; the new building was opened by Queen Elizabeth II on 21 November 1967. Florey pursued a more progressive and internationalist outlook for the Royal Society. He hosted Yuri Gagarin at a luncheon at Burlington House, and led Royal Society visits to Russia in 1965 and 1967.
A relatively short-range dating technique is based on the decay of uranium-234 into thorium-230, a substance with a half-life of about 80,000 years. It is accompanied by a sister process, in which uranium-235 decays into protactinium-231, which has a half-life of 32,760 years. While uranium is water-soluble, thorium and protactinium are not, and so they are selectively precipitated into ocean-floor sediments, from which their ratios are measured. The scheme has a range of several hundred thousand years. A related method is ionium–thorium dating, which measures the ratio of ionium (thorium-230) to thorium-232 in ocean sediment.
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.